TAVR for Bicuspid Aortic Valve Stenosis

Jung-Min Ahn, MD

Division of Cardiology, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea







Challenges of TAVR in BAV

Anatomical Features

- Heavily calcified leaflet
- Calcified raphe
- Elliptical and larger annulus
- Dilated and/or horizontal aorta
- Lack of standardized annulus measurements









Current Evidence of TAVR in BAV

	Мую	Yousef ²	
	Sapien (n=48)	CoreValve (n=91)	All* (n=108)
Age, years	78 ±10	78±8	76±14
STS (%)	5.0 ± 3.9	4.8 ± 3.1	_
Log EuroSCORE (%)	15.3 ± 10.7	14.5 ± 10.7	17.2 ± 12.2
Post AR ≥ mild (%)	19.6	32.2	25.2
Post AR ≥ moderate (%)	6.5	5.5	9.6
PPM (%)	6.5	5.5	19.4
30-day mortality (%)	6.3	4.9	8.3
1-year mortality (%)	20.8	12.5	16.9

¹Mylotte, et al., *JACC* 2014; 64: 2330-39; ²Yousef, et al., Int *J Cardiol* 2015; 189: 282-8

*Sapien (n=61) and CoreValve (n=47)

Remaining Issues

1. Relatively younger and lower-risk group

Direct Comparison of Outcomes After TAVR in Bicuspid vs. Tricuspid AS

2. Evolution of TAVR devices

New-generation devices (SAPIEN 3 and Lotus) vs. Old-generation devices (SAPIEN XT and CoreValve)





Bicuspid TAVR Registry

NCT 02394184


Total	Old-generation devices		
(n=301)	(n=199)		
	Sapien XT (n=87)	CoreValve (n=112)	

20 centers from 14 countries in Europe, North America and Asia-Pacific





Outcomes of TAVR in Bicuspid vs. Tricuspid AS







TAVR in Bicuspid vs. Tricuspid AS Baseline Characteristics

	Bicuspid AS (N = 199)	Tricuspid AS (N = 2649)	p value
Age	77.0±8.9	82.0±6.4	< 0.001
Male	64.8%	48.0%	< 0.001
NYHA class III/IV	74.4%	76.5%	0.49
Logistic EuroSCORE	15.0±11.2	16.8 ± 11.8	0.03
STS score	4.6±5.1	5.7±5.2	0.02
Diabetes mellitus	20.6%	26.5%	0.07
Hypertension	60.3%	73.4%	< 0.001
Previous stroke	15.1%	10.9%	0.07
Peripheral vascular disease	11.1%	16.8%	0.03
Previous PCI	19.1%	27.6%	0.009
Previous CABG	7.5%	13.8%	0.01
LVEF, %	53±15	55±13	0.06

TAVR in Bicuspid vs. Tricuspid AS Procedural Outcomes

	Bicuspid AS (N = 199)	Tricuspid AS (N = 2649)	p value
Procedural related death	1.5%	1.5%	> 0.99
Annulus rupture	2.0%	0.5%	0.02
Second valve implantation	6.5%	3.0%	0.006
New PPM	13.1%	13.9%	0.76
Post-AR > mild	17.6%	10.9%	0.004
Device success	72.9%	85.0%	< 0.001




TAVR in Bicuspid vs. Tricuspid AS30-day Outcomes

	Bicuspid AS (N = 199)	Tricuspid AS (N = 2649)	p value
All stroke	2.5%	2.0%	0.60
Life-threatening bleeding	3.5%	6.5%	0.10
Major vascular complicati ons	4.5%	6.6%	0.24
AKI stage 2-3	2.5%	3.1%	0.63
Early safety endpoints	15.1%	17.4%	0.41
30-day mortality	4.5%	4.9%	0.79




TAVR in Bicuspid vs. Tricuspid AS SAPIEN XT






TAVR in Bicuspid vs. Tricuspid AS CoreValve








CVRF

TCT



CVRF

TCT

TAVR for Bicuspid AS with SAPIEN XT and CoreValve



1. Long-term Mortality was comparable to Tricuspid AS

2. Lower Device Success Rate

- Annulus Rupture with SAPIEN XT
- Paravalvular Leak with CoreValve

Advance with New-generation devices??





Bicuspid TAVR Registry

NCT 02394184

Total (n=301)	Early-generation devices (n=199)		New-generation devices (n=102)	
	SAPIEN XT	CoreValve	SAPIEN 3	Lotus
	(n=87)	(n=112)	(n=91)	(n=11)

20 centers from 14 countries in Europe, North America and Asia-Pacific



J Am Coll Cardiol. 2016. In Press



The Bicuspid TAVR Registry Baseline Characteristics

	Overall (N = 301)	Old devices (N = 199)	New devices (N = 102)	p value
Age	77.0± 9.2	77.0±8.9	77.0±9.8	0.97
Male	57.5%	64.8%	43.1%	< 0.001
NYHA class III/IV	74.1%	74.4%	73.5%	0.88
Logistic EuroSCORE	14.9±11.7	15.0±11.2	14.7±12.8	0.88
STS score	4.7±5.2	4.6±5.1	4.9±5.4	0.57
Previous stroke	16.3%	15.7%	18.6%	0.43
Peripheral vascular disease	12.6%	11.1%	15.7%	0.42
COPD	17.3%	18.1%	15.7%	0.60
LVEF, %	51±15	53±15	48±16	0.004
CARDIOWASCLEAR SUMMIT				<u>~</u>


J Am Coll Cardiol. 2016. In Press

TCTAP 2016


The Bicuspid TAVR Registry Procedural Data

	Overall (N = 301)	Old devices (N = 199)	New devices (N = 102)	p value
Transfemoral access	84.1%	78.4%	95.1%	< 0.001
Device type				
Sapien XT	_	87 (43.7%)	_	< 0.001
CoreValve	_	112 (56.3%)	_	
Sapien 3	_	_	91 (89.2%)	
Lotus	_	_	11 (10.8)	
Type of bicuspid				
Туре 0	11.9%	13.0%	10.1%	
Туре 1	86.2%	84.5%	88.9%	
Type 2	1.9%	2.5%	1.0%	

New- vs. Old-generation Devices Post Aortic Regurgitation




New- vs. Old-generation Devices Device success



J Am Coll Cardiol. 2016. In Press

New- vs. Old-generation Devices 30-day Outcomes



J Am Coll Cardiol. 2016. In Press

CVRF

Conclusions

- 1. Comparable Short- and long-term Mortality
- 2. Lower Device Success Rate with old-generation devices
 - Annulus Rupture with SAPIEN XT (4.6%)
 - Paravalvular Leak with CoreValve
- 3. New-generation devices showed excellent outcomes
 - NO moderate or severe Paravalvular Leak
 - Improved Device Success

4. Long-term outcomes with new-generation devices need to be evaluated



